Compare BridgeBio Pharma Inc (BBIO) vs Rivian Automotive, Inc. (RIVN) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Rivian Automotive (RIVN) trades at $16.00, up 4.03% today, with a bullish technical signal and support at $15–16. The company reported Q2 2026 EPS of -$0.47, beating estimates, and raised 2026 delivery guidance to 65,000–70,000 vehicles. Revenue grew to $5.39B in 2025, but net losses persist at -$3.65B, with cash flow negative. Analyst consensus is mixed, with a $18.70 price target and 48% buy ratings.

Outlook hinges on R2 SUV ramp-up and cost controls, with potential for margin improvement by late 2026. Key risks include high cash burn, execution delays, and EV market competition. Upside exists if profitability targets are met, but investors face volatility amid funding needs and sector headwinds.